Hypertension (HTN) is a leading contributor to cardiovascular morbidity and mortality, yet its management is often complicated by coexisting conditions. This narrative review addresses the challenge of HTN in a complex clinical landscape by proposing a new framework of clinically...
Open access
Research Article10.9734/ajcr/2025/v8i1331
Tucatinib is a highly selective tyrosine kinase inhibitor targeting the HER2 protein, representing a significant advancement in treating HER2-positive metastatic breast cancer (MBC), including cases with brain metastases. This review assesses the efficacy and safety of tucatinib...
Lung cancer remains the leading cause of cancer-related death globally, with non-small cell lung cancer (NSCLC) accounting for most cases. A critical subset of NSCLC is characterized by anaplastic lymphoma kinase (ALK) gene rearrangements, which drive tumor growth and progression...
Background: Non-alcoholic steatohepatitis (NASH) is emerging as a significant global health challenge, closely linked to obesity and metabolic disorders. Despite its increasing prevalence, effective pharmacotherapy remains limited. Resmetirom, a selective thyroid hormone receptor...
Hypertension, a major modifiable risk factor for cardiovascular disease and global mortality, affects approximately 31.1% of adults worldwide. Resistant hypertension, observed in 13-30% of hypertensive patients, poses a challenge in treatment escalation, contributing to clinical...